Shanghai, China-headquartered pharmatech company WuXi (NYSE: WX) has acquired NextCODE Health, a genomic analysis and bioinformatics company based in the USA.
The acquisition was made for $65 million in cash, and WuXi plans to merge its genome center with NextCODE Health to form a new company, WuXi NextCODE Genomics. The business will be headquartered in Shanghai and have operations in Cambridge, Massachusetts, and Reykjavik, Iceland.
Ge Li, chairman and chief executive of WuXi Pharmatech, said: "With the huge unmet medical needs in diseases with a genetic component and the rapid advances in genomics and bioinformatics, now is the right time for WuXi to make a strategic investment in this field, and NextCODE is the right partner. This new venture of WuXi NextCODE Genomics will create important new genomic and bioinformatic products and services to help make personalized treatment and medicine a reality. It will also enable doctors to provide better treatments to patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze